Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Dermato-Onco2024 | Neoadjuvant atezolizumab for advanced cutaneous squamous cell carcinoma

Vasu Divi • 28 Oct 2024
Dermato-Onco2024
Skin Cancer Antibodies Atezolizumab Checkpoint Inhibitors

Vasu Divi, MD, Stanford Medicine, Stanford, CA, shares results from a Phase II trial (NCT04710498) of neoadjuvant atezolizumab prior to surgical resection in patients with advanced cutaneous squamous cell carcinoma (cSCC). Atezolizumab was well-tolerated in patients with advanced cSCC and demonstrated a high rate of major and complete pathologic response to the treatment. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Vasu Divi

Identifying biomarkers in cutaneous SCC for enhanced patient screening
0:35
Identifying biomarkers in cutaneous SCC for enhanced patient screening
Vasu Divi • 28 Oct 2024
Developing personalized treatments for patients with cutaneous SCC
0:40
Developing personalized treatments for patients with cutaneous SCC
Vasu Divi • 28 Oct 2024
The future role of neoadjuvant immunotherapies in advanced cSCC
0:43
The future role of neoadjuvant immunotherapies in advanced cSCC
Vasu Divi • 28 Oct 2024

Related Videos

Predictors of toxicity and tolerability with lifileucel in advanced melanoma
1:18
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh • 30 May 2026
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
1:00
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
Alexandra Haugh • 30 May 2026
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
2:41
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
Alexandra Haugh • 30 May 2026
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
1:05
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
James Smithy • 31 May 2026
The content of VJOncology is intended for healthcare professionals